TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7055526
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia with thiopentone, fentanyl and nitrous oxide, infusion of isotonic saline solution 15 ml min‐1 (Group II)
Study: 29241582
Drug: 10/20‐PRO (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10/20‐PRO (10 g protein followed by 20 g whey protein isolate 120 minutes later)
Study: 29241582
Drug: 30‐PRO (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30‐PRO (30 g protein breakfast)
Study: 29241582
Drug: 10‐PRO (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐PRO (10 g protein breakfast, control)
Study: 24307240
Drug: DTaP5 (five-component
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP5 (five-component acellular pertussis vaccine)
Study: 24307240
Drug: DTwP (whole-cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP (whole-cell pertussis vaccine)
Study: 24307240
Drug: DTaP2 (two-component
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP2 (two-component acellular pertussis vaccine)
Study: 24307240
Drug: No vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccine (1997 seroprevalence study)
Study: 20214328
Drug: Western medical
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medical routine therapy combined with QQG
Study: 20214328
Drug: Western medical
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medical routine therapy with placebo
Study: 15590360
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day + vitamin C 500 mg/day
Study: 15590360
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day + vitamin E 400 IU/day
Study: 11328193
Drug: Losigamone (3x500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losigamone (3x500 mg/die)
Study: 3110200
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) 2.25 mg/day
Study: 25331194
Drug: Formulations containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations containing HPC with intrinsic viscosities above 9 dL/g and in quantities above 30%
Study: 25331194
Drug: Formulations containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations containing HPMC with intrinsic viscosities above 9 dL/g and in quantities above 30%
Study: 24780407
Drug: Low-dose subconjunctival
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subconjunctival cyclosporine A (CsA) implants
Study: 24780407
Drug: High-dose subconjunctival
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose subconjunctival cyclosporine A (CsA) implants
Study: 24780407
Drug: Placebo (carrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (carrier only) implants
Study: 9578342
Drug: Antioxidant fortified
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant fortified margarine (15 g/d providing 121 mg vitamin C, 31 mg vitamin E, 2.7 mg alpha‐carotene, and 5.3 mg beta‐carotene)
Study: 18800453
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium 50 mg once or twice daily, or 100 mg once daily
Study: 2804253
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of test or reference drug
Study: 2804253
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of test or reference drug
Study: 2804253
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of phenytoin
Study: 2804253
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of phenytoin
Study: 985661
Drug: Tobramycin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 1.5 mg/kg or 80 mg administered via rapid intravenous injection
Study: 985661
Drug: Tobramycin dosage
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin dosage interval of 6 hr with a total dosage of 6 mg/kg per day
Study: 30444982
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (20 mL of 2% lidocaine gel)
Study: 28692301
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (3.5 mg or 140,000 IU biweekly for 8 weeks)
Study: 21135313
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment with citalopram followed by up to 3 sequential next‐step treatments.
Study: 11240973
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg twice a day for 7 days) + Mexiletine (200 mg on the eighth day)
Study: 11240973
Drug: Mexiletine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (200 mg alone)
Study: 7755478
Drug: Cilazapril (CIL)
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (CIL) 10 mg per day (n=6)
Study: 2790919
Drug: Hydroxychloroquine sulphate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine sulphate, 20 mg/day for one year
Study: 1255309
Drug: Chloramphenicol treatment
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol treatment
Study: 30678744
Drug: Individual psychological
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual psychological treatments (Healthy Activity Program for depression)
Study: 12908854
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily and caffeine 100 mg three times daily
Study: 12908854
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily and caffeine 100 mg three times daily
Study: 12799847
Drug: Tilidine/naloxone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine/naloxone 50 mg
Study: 12799847
Drug: Tilidine/naloxone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine/naloxone 100 mg
Study: 12799847
Drug: Codeine 100
Normalized name: codeine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 100 mg
Study: 12799847
Drug: Tilidine/naloxone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine/naloxone 50 mg and 100 mg
Study: 12799847
Drug: Codeine 50
Normalized name: codeine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 50 mg and 100 mg
Study: 1829465
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day acitretin
Study: 1829465
Drug: Acitretin therapy
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin therapy after placebo
Study: 25243325
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg od
Study: 25243325
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 10 mg od
Study: 16442114
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) with estradiol +/- medroxyprogesterone
Study: 14579993
Drug: High starting
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High starting dose: 1 mg budesonide inhalation suspension twice daily for 8 days (n = 11)
Study: 14579993
Drug: Low starting
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low starting dose: 0.25 mg budesonide inhalation suspension twice daily for 8 days (n = 11)
Study: 1283931
Drug: Local, laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local, laparoscopic Prostaglandin‐injection
Study: 30482661
Drug: Bladder-sparing tri-modality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder-sparing tri-modality therapy (TMT)
Study: 29505578
Drug: DOT (Directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOT (Directly Observed Treatment)
Study: 29505578
Drug: NDOT (Non-Directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDOT (Non-Directly Observed Treatment)
Study: 24518370
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg or 1600 μg of salbutamol
Study: 20016461
Drug: AKL-0707 (GH-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKL-0707 (GH-releasing hormone super-agonist)
Study: 17401781
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean dose 12.3 mg/day)
Study: 17401781
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose 5.2 mg/day)
Study: 7756097
Drug: Immediate Release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release (IR) formulation (100 mg levodopa/25 mg genserazide)
Study: 7756097
Drug: Controlled Release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled Release (CR) formulation (300 mg levodopa/75 mg benserazide)
Study: 7465474
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of glucose a day
Study: 7465474
Drug: 129 g
Normalized name: Xenon Xe 129 Gas Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: 129 g of glucose a day
Study: 30644570
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of mirabegron (50 mg) and solifenacin (5 mg)
Study: 30644570
Drug: Solifenacin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin monotherapy
Study: 30644570
Drug: Mirabegron monotherapy
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron monotherapy
Study: 27830922
Drug: Psychomotor treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychomotor treatment (group A)
Study: 15271731
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine 150 microg diluted with 9 mL of normal saline 30 min before surgery and PCEA with morphine (0.1 mg/mL) and clonidine (1.5 microg/mL) in 0.2% ropivacaine 100 mL after surgery
Study: 15271731
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 10 mL before surgery and PCEA with morphine and ropivacaine after surgery
Study: 11563588
Drug: Novel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel treatment strategies (nonmyeloablative allogeneic transplantation, vaccination)
Study: 8513525
Drug: Ondansetron (antiemetic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (antiemetic, selective serotonin 5-HT3 receptor antagonist) administered via rapid intravenous infusion over two minutes.
Study: 8513525
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group) administered via rapid intravenous infusion.
Study: 14591143
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Suloctidil daily
Study: 14591143
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg Suloctidil daily
Study: 17688420
Drug: Normal-sodium diet
Normalized name: sulfacetamide sodium Medicated Pad [Rosula NS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-sodium diet (120 mmol sodium) plus oral furosemide [250‐500 mg, b.i.d.]
Study: 17688420
Drug: Low-sodium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium diet (80 mmol sodium) plus oral furosemide [250‐500 mg, b.i.d.]
Study: 10350104
Drug: Subgroup 1
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup 1 (TnT peak < 1 ng/ml)
Study: 10350104
Drug: Subgroup 2
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup 2 (TnT peak between 1 and 3 ng/ml)
Study: 10350104
Drug: Subgroup 3
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup 3 (TnT peak > 3 ng/ml)
Study: 7859141
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) 600 mg/day plus acyclovir (ACV) 4,800 mg orally per day
Study: 7859141
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) 600 mg/day plus placebo
Study: 1838032
Drug: Cilazapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (2.5 mg once daily)
Study: 7171073
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance therapy (MMTP)
Study: 6423586
Drug: Naloxone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusion (0.4 mg/ml saline)
Study: 6423586
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline infusion 1 ml)
Study: 6423586
Drug: Placebo (infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (infusion control)
Study: 27143669
Drug: Universal decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal decolonization treatment with chlorhexidine bathing and nasal mupirocin
Study: 22571408
Drug: Neridronate 100
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neridronate 100 mg intravenously every 90 days
Study: 22571408
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (500 mg calcium with 400 iu vitamin D daily)
Study: 12423628
Drug: Acipimox (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (an inhibitor of lipolysis) with GH
Study: 9862828
Drug: L‐NMMA 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA 2 mg/kg/h
Study: 9862828
Drug: L‐NMMA 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA 4 mg/kg/h
Study: 9862828
Drug: L‐NMMA 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA 0.5 mg/kg/h
Study: 7537524
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of all-trans retinoic acid (ATRA) and granulocyte-colony stimulating factor (G-CSF)
Study: 7537524
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of ATRA, G-CSF, erythropoietin (Epo), and tocopherol
Study: 7537524
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of ATRA and cytokines
Study: 7033013
Drug: Sulphadiazine/trimethoprim (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadiazine/trimethoprim (1 g daily for 10 days)
Study: 7033013
Drug: Sulphamethoxazole/trimethoprim (1.92
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphamethoxazole/trimethoprim (1.92 g B.I.D for 10 days)
Study: 29605360
Drug: Intraoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative treatment with paracetamol
Study: 27468022
Drug: Epinephrine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.1 mg/kg i.m.)
Study: 27468022
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (0.9% saline, at 0.1 ml/kg i.m.)
Study: 23184162
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of fluoride gel using a toothbrush
Study: 23184162
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of fluoride gel using a tray (control)
Study: 17397734
Drug: Stromal hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stromal hydration (using fortified balanced salt solution [BSS Plus])
Study: 25782693
Drug: Home-based telemonitored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based telemonitored robotic-assisted therapy (HMP) combined with home exercise program (HEP) for 3 hours/day, 5 days/week for 8 weeks
Study: 25782693
Drug: Home exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercise program (HEP) only at identical dosage
Study: 19514485
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (close reduction and immobilization in a plastofit splint)
Study: 19514485
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (percutaneous fixation by Kirschner‐wires)
Study: 16705315
Drug: KSHV latent
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KSHV latent antibodies
Study: 16705315
Drug: KSHV lytic
Normalized name: Fytic acid
DrugBank: Phytic acid (DB14981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KSHV lytic antibodies
Study: 16705315
Drug: Anti-EBV antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-EBV antibodies
Study: 16705315
Drug: Antibody levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody levels against EBV
Study: 16705315
Drug: Antibodies against
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies against KSHV (latent and lytic)
Study: 15298070
Drug: Newer generation
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer generation antidepressants
Study: 9401312
Drug: Serotonergic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonergic agents
Study: 8260542
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered immunoglobulins (IVIG)
Study: 8260542
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IVIG treatment)
Study: 22689290
Drug: Transcranial Magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Magnetic Stimulation (TMS) taper
Study: 22689290
Drug: Continuation pharmacotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation pharmacotherapy or naturalistic follow-up after TMS taper
Study: 20367092
Drug: Fully etched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully etched test implants
Study: 20367092
Drug: Hybrid control
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid control implants
Study: 18723908
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) 0.5 g/kg (low dose group)
Study: 18723908
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) 1.0 g/kg (high dose group)
Study: 18723908
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (0.5 g/kg and 1.0 g/kg)
Study: 8739021
Drug: Squalene 860
Approvals — FDA: no, EMA: no, PMDA: no
Description: Squalene 860 mg
Study: 8739021
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Pravastatin 10 mg + Squalene 860 mg)
Study: 3700343
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with lecithin and ergoloid mesylates
Study: 26969660
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (loading dose with 50 mg/kg over 10 min and then 15 mg/kg/h by continuous infusion)
Study: 21834964
Drug: Ongoing information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing information as to the natural history of the condition and treatment as usual
Study: 19350305
Drug: Long-term chemoradiotherapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term chemoradiotherapy (RT/CTx) as standard treatment for locally advanced rectal cancer.
Study: 19350305
Drug: Quality controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality controlled principles of radical surgery (partial vs total mesorectal excision) followed by adjuvant chemotherapy.
Study: 17352947
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation for 8 weeks
Study: 17352947
Drug: Baseline (pre-treatment)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (pre-treatment)